OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Husain on the Future of Monitoring T790M in Lung Cancer

March 24th 2017

Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).

Dr. Evans on Challenges of Immunotherapy in Lung Cancer

March 24th 2017

Tracey L. Evans, MD, associate professor of Clinical Medicine at Penn Medicine, discusses the challenges associated with immunotherapy for the treatment of patients with lung cancer.

Dr. Jackson on Ongoing Challenges in Treating Patients With Multiple Myeloma

March 24th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

Dr. Swisher on Efficacy Results of ARIEL 2 Study in Ovarian Cancer

March 24th 2017

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

Dr. Usmani on Mechanisms and Response Rates With Daratumumab in Myeloma

March 24th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the mechanisms of daratumumab (Darzalex) as well as the reported response rates in combination with other agents in multiple myeloma.

Dr. Thompson on the Future of Treatment in Multiple Myeloma

March 24th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses the future of treatment in multiple myeloma.

Dr. Dreicer on Abiraterone and Enzalutamide in Prostate Cancer

March 24th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Seiwert on Advice With Immunotherapy for Head and Neck Cancer

March 23rd 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, gives advice to community oncologists on administering immunotherapy to patients with head and neck cancer.

Dr. Kudchadkar on the FDA Approval of Avelumab in Merkel Cell Carcinoma

March 23rd 2017

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses the FDA approval of avelumab for the treatment of patients with Merkel cell carcinoma.

Dr. Landgren on Using Daratumumab for Patients With Multiple Myeloma

March 23rd 2017

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses using daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Dr. Koyfman on Informing Patients of Reirradiation for Head and Neck Cancer

March 23rd 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses informing patients of reirradiation as a treatment for head and neck cancer.

Dr. Jahanzeb on the Future of Adjuvant Therapy in HER2+ Breast Cancer

March 22nd 2017

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the future of adjuvant treatment in HER2-positive breast cancer.

Dr. Rai on Handicaps of Chemotherapy in CLL

March 22nd 2017

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the downfalls of chemotherapy in chronic lymphocytic leukemia (CLL).

Dr. Tripathy on Standard and Emerging Treatment Advances for HER2+ Breast Cancer

March 22nd 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses standard and emerging advances in the treatment of patients with HER2-positive breast cancer.

Dr. Garfall on Impact of CAR T-Cell Therapy in Hematologic Malignancies

March 22nd 2017

Alfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Dr. Slovin on the Role of Immunotherapy for Prostate Cancer

March 22nd 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current role of immunotherapy in patients with advanced prostate cancer.

Dr. Vokes on Biomarker Selection in Head and Neck Cancer

March 22nd 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.

Dr. Abida on Genetic Testing for Prostate Cancer

March 21st 2017

Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses genetic testing for patients with prostate cancer.

Dr. Hope on Imaging for Neuroendocrine Tumors

March 21st 2017

Thomas Hope, MD, assistant professor, UCSF Helen Diller Family Comprehensive Cancer Center, discusses imaging for patients with neuroendocrine tumors (NETs).

Dr. Wilky on Ongoing Trial of Pembrolizumab and Axitinib in Sarcoma

March 21st 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the status of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.